Myeloma, Multiple Clinical Trials

17 recruitingLast updated: June 18, 2026

There are 17 actively recruiting myeloma, multiple clinical trials across 10 countries. Studies span Phase 2, Not Applicable, Phase 1. Top locations include Oslo, Norway, Philadelphia, Pennsylvania, United States, Atlanta, Georgia, United States. Updated daily from ClinicalTrials.gov.


Myeloma, Multiple Trials at a Glance

17 actively recruiting trials for myeloma, multiple are listed on ClinicalTrialsFinder across 6 cities in 10 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Oslo, Philadelphia, and Atlanta. Lead sponsors running myeloma, multiple studies include IRCCS Azienda Ospedaliero-Universitaria di Bologna, Assistance Publique - Hôpitaux de Paris, and Abramson Cancer Center at Penn Medicine.

Browse myeloma, multiple trials by phase

Treatments under study

About Myeloma, Multiple Clinical Trials

Looking for clinical trials for Myeloma, Multiple? There are currently 17 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Myeloma, Multiple trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Myeloma, Multiple clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 117 of 17 trials

Recruiting

Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With MM or MGUS

Monoclonal Gammopathy of Undetermined SignificanceMyeloma, Multiple
University Hospital, Rouen300 enrolled2 locationsNCT06559033
Recruiting
Phase 1

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

Multiple MyelomaMyelomaMyeloma, Multiple
K36 Therapeutics, Inc.165 enrolled22 locationsNCT05651932
Recruiting

Infectious Complications in Hematological Patients Under Treatment With Bispecific Antibodies.

severe infectionMyeloma, MultipleCMV Reactivation+3 more
Infanta Leonor University Hospital350 enrolled2 locationsNCT07609576
Recruiting

MMAPPIN' Study: Multiple Myeloma Analysis For Patient-specific Insights to Dissect Disease Heterogeneity

Myeloma, Multiple
IRCCS Azienda Ospedaliero-Universitaria di Bologna520 enrolled1 locationNCT07582354
Recruiting

Anonymization of Clinical Data From Pseudonymized Databases Collected as Part of Previus Clinical Trials on Multiple Myeloma

Myeloma, Multiple
IRCCS Azienda Ospedaliero-Universitaria di Bologna600 enrolled1 locationNCT07283224
Recruiting
Phase 1

A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

NeoplasmLymphoproliferative DisordersNeoplasms by Histologic Type+11 more
Kelonia Therapeutics, Inc.70 enrolled7 locationsNCT07075185
Recruiting
Phase 2

Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

Myeloma, Multiple
M.D. Anderson Cancer Center94 enrolled1 locationNCT05091372
Recruiting
Not Applicable

Feasibility of a Multi-omics Platform for Hematological Malignancies

Acute LeukemiaChronic LeukemiaLymphoproliferative Disorders+3 more
Azienda Ospedaliero-Universitaria di Parma1,040 enrolled1 locationNCT07445438
Recruiting
Phase 2

A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment

MyelomaMyeloma, Multiple
AHS Cancer Control Alberta100 enrolled2 locationsNCT04268199
Recruiting
Not Applicable

e-Motion : Promoting Emotion Regulation in Chronic Cancer

Myeloma, MultipleMetastatic Cancers
Université Libre de Bruxelles30 enrolled2 locationsNCT07236021
Recruiting
Phase 2

Limited-duration Teclistamab

Myeloma, Multiple
Abramson Cancer Center at Penn Medicine75 enrolled5 locationsNCT05932680
Recruiting

High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)

Multiple MyelomaMyelodysplastic SyndromeLymphoma+12 more
Yigeng Cao,MD,PhD1,000 enrolled1 locationNCT07205523
Recruiting
Not Applicable

Evaluation of the Role of Connected Scales in the Therapeutic Care of Hematology Patients

Lymphoma, Non-HodgkinMyeloma, Multiple
Assistance Publique - Hôpitaux de Paris30 enrolled1 locationNCT06133426
Recruiting
Phase 1Phase 2

The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors

AML (Acute Myelogenous Leukemia)B-ALLMyeloma, Multiple+3 more
Tianjin Medical University General Hospital90 enrolled1 locationNCT06911710
Recruiting

The Norwegian Immunotherapy in Multiple Myeloma Study

Plasma Cell LeukemiaMyeloma, MultipleAL Amyloidosis
St. Olavs Hospital400 enrolled23 locationsNCT06855121
Recruiting

Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma

Myeloma, Multiple
Uppsala University100 enrolled1 locationNCT06245629
Recruiting

Fluciclovine PET/CT in Multiple Myeloma Patients

PET/CTMyeloma, Multiple
Oslo University Hospital10 enrolled1 locationNCT03966443